FDA still not ready to go back to actual in-person meetings with biopharma sponsors
Since the Covid pandemic began in 2020, the FDA has shuttered its White Oak, MD, doors to outside companies not only seeking input on their developing assets, but for adcomm meetings too.
As of today, the FDA says nothing is changing in the near term with respect to a re-opening, although the agency has updated how it defines in-person meetings to include Zoom meetings with cameras on.
“This means face-to-face meetings will only be virtual at this time,” the agency said in a statement. “Once FDA returns to in-person meetings, sponsors/applicants will be notified of that option for a face-to-face meeting.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
